Biotech Values

[jq1234]

I don't think the PR specified a stat sig improvement.

I take "with superior reductions in post-prandial glucose excursions in the PH20 insulin analog arms." as stat significant.

Do you view this news for HALO's analog as bullish, bearish, or neutral for BIOD and its potentially improved analog?

I really don't know what BIOD's approach to analog is, thus tough to say. If it were for UF HI, I would say neutral. For analog, if I have to give an answer, I have to say neutral to bearish simply because someone else succeeded in similar area and well ahead of your development.

As I said before, insulin has big enough market to allow two UFI players.

I would think LLY might be more inclined to partner with BIOD

I'd say SNY is more likely. SNY's Apidra is newer rapid analog, that is lagging the other two. To me, it is more likely to be modified to differentiate itself from the other two. HALO used Apidra as leading in titration period in their phase 2 trial. So it hasn't been tested by HALO in combination with PH20. HALO on the other hand might be interesting to both NVO/LLY and other insulin biosimilar programs.